NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management | According to DataM Intelligence

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected ...
Seeking Alpha

Navigating The NASH Storm: Intercept Pharmaceuticals' Uncertain Voyage

Obeticholic acid (OCA) has shown potential for treating NASH with fibrosis, demonstrating improvements in liver histology, inflammation, and steatosis. Safety concerns, including liver injury and ...
MedPage Today

Resmetirom Poised to Become First NASH Treatment

Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Resmetirom ...
Yahoo

Intercept to go back to FDA with its NASH treatment application

(Reuters) -Intercept Pharmaceuticals Inc will resubmit its application for approval of its therapy for a chronic liver disease to the U.S. Food and Drug Administration, two years after the regulator ...
WCBD

Current NASH treatment hurdles highlighted, new drugs hailed as game-changers

Fatty Liver Alliance advocates about the importance of 2 new NASH treatments soon to be approved. ICER welcomes public comments and discussion about new NASH drugs. NASH: Gastric bypass, diet, ...
Seeking Alpha

2 Factors That Will Determine NASH Treatment Sales

The NASH treatment market will have significant dependence on two underappreciated indirect factors that are largely undetermined at this point. The size of the addressable NASH market will depend on ...

DataM Intelligence 4 Market Research LLP: NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management ...

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected to ...